Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2017

View Archived Issues

Proteostasis Therapeutics files IND with FDA for CFTR potentiator

BMS-986016 in combination with nivolumab shows promise for the treatment of melanoma

[68Ga]NOTA-RM-26 detects breast cancer in pilot study

FDA approves Gleolan intraoperative imaging agent for malignant glioma

First-in-human trial data reported for antibody-drug conjugate IMGN-779

Phase I results for LY-3022855 in patients with advanced solid tumors

Genentech presents phase Ib data for GDC-0919 and atezolizumab in advanced solid tumors

FDA awards fast track designation to Synlogic's SYNB-1020

European Commission approves Kevzara for rheumatoid arthritis

Rhythm and Camurus report initial phase Ia results on extended-release setmelanotide

STK-01 set to move into phase I trial for bladder cancer under new agreement

Danazol shows promise for treating MDS-associated thrombocytopenia

Skin-derived neural precursor cells improve canine model of Alzheimer's disease

Heinrich-Heine-Universitaet Duesseldorf patents NMDA receptor antagonists

Centro de Investigacion Biomedica en Red and collaborators divulge AMPK activators

FDA awards orphan drug designation to Propanc's PRP for pancreatic cancer

Wockhardt presents compounds for treating bacterial infections

Teijin Pharma discovers androgen receptor agonists

Horizon completes sale of Procysbi and Quinsair rights in EMEA

Clarus resubmits NDA for Jatenzo

Merck & Co. discloses leukotriene BLT1 receptor antagonists

Bluebird reports interim data from Starbeam study of Lenti-D in cerebral adrenoleukodystrophy

pSivida submits MAA in E.U. for Durasert 3-year treatment for posterior segment uveitis

Stivarga for HCC approved in Japan, recommended for approval in E.U.

OSE pauses new patient recruitment in phase III NSCLC study of Tedopi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...